It’s only fair to share… Tibremciclib cas 2397678-18-9, GTPL12881 CRB7BT5JDQ 518.6 g/mol, C28H32F2N8 N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-[(1R)-6-fluoro-1-methyl-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-8-yl]pyrimidin-2-amine Tibremciclib is a CDK4 inhibitor with antineoplastic activity[1]. 13 Sep 2024 Efficacy and adverse event data from a phase III trial in Breast cancer presented at the 49th European Society for Medical Oncology Congress 2024 (ESMO-2024) Cyclin-dependent kinases (CDKs) are a class of serine …